ALUR

Allurion Technologies Inc

Add to Watchlist

Advanced Chart

2.730

-0.06(-2.151%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

2.8477

Open

2.780

VWAP

2.78

Vol

42.82K

Mkt Cap

20.36M

Low

2.700

Amount

118.92K

EV/EBITDA(TTM)

Total Shares

47.97M

30.91M

EV/OCF(TTM)

P/S(TTM)

0.29

Allurion Technologies, Inc. offers Allurion Program, which is a weight loss platform that combines the Allurion Gastric Balloon for weight loss. The Company offers Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Balloon is swallowed as a capsule under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia. The Allurion Balloon is a procedure-less intragastric balloon that does not require any surgery, endoscopy, or anesthesia for placement. The balloon is swallowed in a capsule during a discrete outpatient office visit that takes approximately 15 minutes (though times may vary across different outpatient offices). The Allurion Virtual Care Suite is a cutting-edge digital therapeutic that combines AI-powered remote patient monitoring tools with a behavior change program.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

9.95M

+77.96%

-0.497

-92.9%

7.18M

+33.69%

-0.643

-85.85%

6.20M

-47.31%

-0.890

-126.06%

Estimates Revision

The market is revising Upward the revenue expectations for Allurion Technologies Inc. (ALUR) for FY2025, with the revenue forecasts being adjusted by 0.09% over the past three months. During the same period, the stock price has changed by 17.17%.

Revenue Estimates for FY2025

Revise Upward

+0.09%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-57.08%

In Past 3 Month

Stock Price

Go Up

+17.17%

In Past 3 Month

4 Analyst Rating

289.38% Upside

Wall Street analysts forecast ALUR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALUR is 10.63 USD with a low forecast of 2.50 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

1 Hold

0 Sell

Strong Buy

289.38% Upside

Current: 2.730

Low

2.50

Averages

10.63

High

18.00

289.38% Upside

Current: 2.730

Low

2.50

Averages

10.63

High

18.00

Chardan Capital

Keay Nakae

Hold

Maintains

$2.5

2025-03-27

Reason

Chardan Capital

Keay Nakae

Price Target

$2.5

2025-03-27

Maintains

Hold

Reason

Chardan notes that Allurion has announced additional data evaluating the use of its Allurion Balloon in combination with patients be treated with GLP1 therapy, which the analyst calls "intriguing," especially the increase in lean body mass. However, the firm believes a more rigorous randomized controlled study will be needed to further validate this finding. Chardan has a Neutral rating and $2.50 price target on Allurion shares.

Roth MKM

Jason Wittes

Strong Buy

Reiterates

$16

2025-03-21

Reason

Roth MKM

Jason Wittes

Price Target

$16

2025-03-21

Reiterates

Strong Buy

Reason

Chardan Capital

Keay Nakae

Hold

Maintains

$2.5

2025-03-21

Reason

Chardan Capital

Keay Nakae

Price Target

$2.5

2025-03-21

Maintains

Hold

Reason

Chardan Capital

Keay Nakae

Strong Buy

Hold

Downgrades

n/a

2024-11-14

Reason

Chardan Capital

Keay Nakae

Price Target

n/a

2024-11-14

Downgrades

Strong Buy

Hold

Reason

Chardan downgraded Allurion Technologies to Neutral from Buy with a price target that is under review after business execution that the firm says "has now been disappointing for the past 4 quarters." The company reported Q3 revenue of $5.4M and further lowered its FY24 revenue guidance to between $30M-$35M, the analyst noted.

TD Cowen

Joshua Jennings

Strong Buy

Initiates

2024-10-02

Reason

TD Cowen

Joshua Jennings

Price Target

2024-10-02

Initiates

Strong Buy

Reason

TD Cowen analyst Joshua Jennings initiated coverage of Allurion Technologies with a Buy rating and $2 price target.

Roth MKM

Jason Wittes

Strong Buy

Initiates

2024-09-06

Reason

Roth MKM

Jason Wittes

Price Target

2024-09-06

Initiates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Allurion Technologies Inc (ALUR.N) is -1.09, compared to its 5-year average forward P/E of -1.62. For a more detailed relative valuation and DCF analysis to assess Allurion Technologies Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.62

Current PE

-1.09

Overvalued PE

0.73

Undervalued PE

-3.97

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.06

Current EV/EBITDA

-5.72

Overvalued EV/EBITDA

-0.68

Undervalued EV/EBITDA

-5.44

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

2.20

Current PS

0.66

Overvalued PS

5.65

Undervalued PS

-1.25

Financials

Annual

Quarterly

FY2025Q1

YoY :

-40.55%

5.58M

Total Revenue

FY2025Q1

YoY :

-36.07%

-7.28M

Operating Profit

FY2025Q1

YoY :

+32.10%

7.38M

Net Income after Tax

FY2025Q1

YoY :

-45.77%

1.54

EPS - Diluted

FY2025Q1

YoY :

-100.00%

N/A

Free Cash Flow

FY2025Q1

YoY :

+1.94%

74.57

Gross Profit Margin - %

FY2025Q1

YoY :

-100.00%

N/A

FCF Margin - %

FY2025Q1

YoY :

+122.21%

132.24

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

24.5K

USD

Months

3-6

26.8K

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 74499900% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

30.0K

Volume

0-12

Months

0.0

Volume

Bought

0-3

1.5M

Volume

Months

3-6

2.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

24.5K

USD

Months

3-6

26.8K

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

ALUR News & Events

Events Timeline

2025-07-22 (ET)

2025-07-22

08:05:55

Allurion publishes long-term weight loss results with Allurion Program

2025-07-09 (ET)

2025-07-09

16:06:58

Allurion Technologies announces distribution partnership with Minogue

2025-07-07 (ET)

2025-07-07

08:06:01

Allurion Technologies submits PMA to FDA, announces additional AUDACITY data

News

9.0

06-17Newsfilter

Allurion Announces Findings from New Studies on Muscle Mass Maintenance in Nearly 20,000 Patients and Four-Year Weight Loss Outcomes at the 2025 Annual Meeting of the ASMBS

9.0

05-27Newsfilter

Allurion Presents Data on Increasing Muscle Mass and Decreasing Fat Mass in Patients Treated With the Allurion Program

9.0

05-14NASDAQ.COM

Allurion To File Final Module Of Weight Loss Balloon To FDA For Approval Next Month